## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.02 indicates fundamental undervaluation.

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($349.35)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Wells Fargo Raises Price Target for Elevance Health (ELV) to $42**
- Source: GuruFocus | 20260107T214220 | Bullish | Relevance: 100%
- Wells Fargo has raised its price target for Elevance Health (ELV) to $424 from $403, maintaining an 'Overweight' rating. This 5.21% increase reflects a positive outlook on the company's market performance. Other analysts have made varied adjustments to ELV's price target, with the average analyst target price being $387.12, indicating a 5.57% upside from the current price.

**2. Top Superinvestors Are Buying Elevance Health (ELV)**
- Source: The Acquirer's Multiple | 20260105T224251 | Bullish | Relevance: 100%
- Several prominent investors, including Glenn Greenberg, Seth Klarman, Jeremy Grantham, and Cliff Asness, significantly increased their holdings in Elevance Health Inc. (ELV) this quarter. This broad-based accumulation signals strong confidence in the company's defensive characteristics, long-term earnings durability, and status as a high-quality healthcare compounder. The buying activity spans value, quantitative, and fundamental investors, reinforcing ELV's appeal across diverse investment strategies.

**3. Elevance Healthâ€™s Stock Holds Its Ground: Defensive Strength In A Market Searching For Direction**
- Source: AD HOC NEWS | 20260105T201816 | Bullish | Relevance: 100%
- Elevance Health's stock has shown consistent growth due to resilient earnings and disciplined capital returns, attracting a "Buy" consensus from Wall Street. Despite market fluctuations, the company's shares reflect a steady, almost stubborn resilience, making it a conviction pick for investors seeking earnings visibility and defensive cash flows. Its strategic shift into value-based care and services, alongside a strong standing in managed care, positions it well for future growth amidst regulatory scrutiny.

**4. Stanley Laman Group Ltd. Cuts Stake in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20260106T112011 | Somewhat-Bullish | Relevance: 100%
- Stanley Laman Group Ltd. significantly reduced its stake in Elevance Health, Inc. by 92% in Q3 2025, selling 7,636 shares and ending with 666 shares valued at $215,000. Despite this, major institutional investors like Norges Bank and Vanguard Group continue to hold substantial positions, contributing to an overall institutional ownership of 89.24%. Elevance Health exceeded Q3 expectations with an EPS of $6.03 and 12% revenue growth, offering an annualized dividend of $6.84, yielding approximately 1.9%.

**5. Wellpoint Data Breach Exposes Protected Health Information (PHI)**
- Source: Claim Depot | 20260105T172804 | Somewhat-Bearish | Relevance: 100%
- Wellpoint, a health insurance provider affiliated with Elevance Health, reported a data breach to the U.S. Department of Health and Human Services on October 7, 2025. The incident involved unauthorized access to sensitive personally identifiable information (PII) and protected health information (PHI), potentially including names, Social Security numbers, medical records, and insurance details. Wellpoint has launched an investigation, secured its systems, and notified affected individuals, advising them to monitor their credit and insurance statements.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-07 | Wells Fargo | $424 | $403 | +5% |
| 2026-01-05 | Barclays | $404 | $385 | +5% |
| 2025-12-19 | Deutsche Bank | $320 | $332 | -4% |
| 2025-12-18 | Morgan Stanley | $352 | $359 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-07 | Wells Fargo | main | Overweight |
| 2026-01-05 | Barclays | main | Overweight |
| 2025-12-19 | Deutsche Bank | down | Hold |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.02 suggests fair value with growth premium. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $82.6B |
| Beta | 0.52 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.02 |
| Forward P/E | 13.7 |
| Current P/E | 12.2 |
| YoY Growth | -10.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 2.4% to 3.5% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.5pp (needs >4.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. AM_20 at 4.5% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.82), confirming momentum. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.54% (CS: 80) | Neutral |
| RSI_14 | 66.6 | Neutral |
| MACD Histogram | 1.82 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 1.092x | Above |
| vs SMA200 | 1.040x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $366.79
- **Stop Loss:** $349.35 (4.8% risk)
- **Target:** $401.67 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 68
- **Position Value:** $24,941.72
- **Portfolio %:** 24.94%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_20*